HTRA4

Across TCGA pan-cancer cohorts, HTRA4 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of HTRA4’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where HTRA4 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types HTRA4 is over-expressed in tumor, although a few such as PAAD and LUSC show the opposite, repressed pattern.

KIRC, HNSC, and KIRP are the cancer types where HTRA4 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in HTRA4 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	+1.368	<.001	11	view →
HNSC	All	III,IV	+0.431	<.001	11	view →
KIRP	Male	All	+1.607	<.001	9	view →
COAD	Female	II,III,IV	+0.552	<.001	9	view →
STAD	All	II,III,IV	+0.743	<.001	8	view →
KICH	All	All	+0.962	<.001	7	view →
BRCA	All	II,III,IV	+0.369	<.001	6	view →
PAAD	All	All	−1.527	.005	4	view →
LUSC	All	All	−0.386	.016	3	view →
THCA	All	All	+0.341	.009	3	view →
LIHC	All	II,III,IV	+0.180	.002	3	view →
BLCA	All	IV	+0.619	.048	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

HTRA4–KIRC

Open the KIRC breakdown →